Cargando…
Engineered adeno-associated virus 3 vector with reduced reactivity to serum antibodies
The natural serotypes of adeno-associated virus (AAV) or their variants, such as AAV8 and AAV5, are commonly used as vectors in the clinical programs for liver-targeted gene therapy. While AAV8 vectors are not highly efficient at targeting primary human hepatocytes, AAV3 vectors have recently demons...
Autores principales: | Ito, Mika, Takino, Naomi, Nomura, Takamasa, Kan, Akihiko, Muramatsu, Shin-ichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084969/ https://www.ncbi.nlm.nih.gov/pubmed/33927271 http://dx.doi.org/10.1038/s41598-021-88614-9 |
Ejemplares similares
-
Reduced Immunogenicity of Intraparenchymal Delivery of Adeno-Associated Virus Serotype 2 Vectors: Brief Overview
por: Hwu, Wuh-Liang, et al.
Publicado: (2022) -
Systemic Delivery of Tyrosine-Mutant AAV Vectors Results in Robust Transduction of Neurons in Adult Mice
por: Iida, Asako, et al.
Publicado: (2013) -
Modifying immune responses to adeno-associated virus vectors by capsid engineering
por: Bentler, Martin, et al.
Publicado: (2023) -
Capsid-specific removal of circulating antibodies to adeno-associated virus vectors
por: Bertin, Berangere, et al.
Publicado: (2020) -
Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats
por: Li, Pengfei, et al.
Publicado: (2019)